Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3607-3615

  Gandhi, Varsha ^a   Plunkett, William ^a   Rodriguez Jr , Carlos O ^a   Nowak, Billie J ^a   Du, Min ^a   Ayres, Mary ^a   Kisor, David F ^a   Mitchell, Beverly S ^a   Kurtzberg, Joanne ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOSIDE; GUANINE ARABINOSIDE; NELARABINE; PRODRUG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; T LYMPHOBLAST;

EID: 0031792644     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3607     Document Type: Article

References (38)

1. Giblett ER, Ammann AJ, Wara DW, et al: Nucleoside phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1:1010-1013, 1975
2. Carson DA, Kaye J, Seegmiller JE: Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Natl Acad Sci USA 74:5677-5681, 1977
3. Carson DA, Kaye J, Matsumoto S, et al: Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA 76:2430-2433, 1979
4. Mitchell BS, Mejias E, Daddona PE, et al: Purinogenic immunodeficiency diseases: Selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci USA 75:5011-5014, 1978
5. Scharenberg JG, Spappen LJ, Rijkers GT, et al: Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Biol 1958:191-199, 1986
6. Cohen A, Lee JWW, Gelfand EW: Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 61:660-666, 1983
7. Ullman B, Martin DW: Specific cytotoxicity of arabinosylguanine toward cultured T-lymphoblasts. J Clin Invest 74:951-955, 1984
8. Shewach DS, Daddona PE, Ashcraft E, et al: Metabolism and selective cytotoxicity of 9-β-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res 45:1008-1014, 1985
9. Verhoef V, Fridland A: Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 45:3646-3650, 1985
10. Shewach DS, Mitchell BS: Differential metabolism of 9-β-arabinofuranosylguanine in human leukemic cells. Cancer Res. 49:6498-6502, 1989
11. Montgomery JA, Shortnacy AT, Carson DA, et al: 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanine: A metabolically stable cytotoxic analogue of 2′-deoxyguanosine. J Med Chem 29:2389-2392, 1986
12. Lambe CU, Averett DR, Paff MT, et al: 2-Amino-6-methoxypurine arabinoside: An agent for T-cell malignancies. Cancer Res 55:3352-3356, 1995
13. Reist EJ, Goodman L: Synthesis of 9-β-D arabinofuranosylguanine. Biochemistry 3:15-18, 1964
14. Krenitsky TA, Koszalka GW, Tuttle JV, et al: An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydrate Res 97:139-146, 1981
15. Green FJ, Lewis RA: Partial purification and characterization of deoxyguanosine kinase from pig skin. Biochem J 183:547-553, 1979
16. Watkins LF, Lewis RA: Phosphorylation of deoxyguanosine in intact and fractured mitochondria. Mol Cell Biochem 77:153-160, 1987
17. Watkins LF, Lewis RA: The metabolism of deoxyguanosine in mitochondria: A characterization of the phosphorylation process which occurs in intact mitochondria. Biochim Biophys Acta 923:103-108, 1987
18. Lewis RA, Link L: Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. Biochem Pharmacol 38:2001-2006, 1989
19. Wang L, Karlsson A, Arnér ESJ, et al: Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 268:22847-22852, 1993
20. Krenitsky TA, Tuttle JV, Koszalka GW, et al: Deoxycytidine kinase from calf thymus: Substrate and inhibitor specificity. J Biol Chem 251:4055-4061, 1976
21. Kurtzberg J, Keating MJ, Moore JO, et al: 2-Amino-9-β-D-arabinosyl-6-methoxy-9H-guanine (GW 506U: Compound 506U) is highly active in patients with T-cell malignancies: Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood 88:669a, 1996 (suppl 7, abstr)
22. Gandhi V, Kisor DF, Rodriguez CC Jr, et al: Pharmacokinetics of arabinosylguanine (ara-G) and its triphosphate (ara-GTP) during a phase I trial of compound GW506U78 in refractory hematologic malignancies: Correlation with response. Blood 88:670a, 1996 (suppl 1, abstr)
23. Plunkett W, Hug V, Keating M, et al: Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 40:588-591, 1980
24. Gandhi V, Danhauser L, Plunkett W: Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-pressure liquid chromatography. J Chromatogr 413:293-299, 1987
25. Sherman PA, Fyfe FA: Enzymatic assay for deoxynucleotide triphosphates using synthetic oligonucleotides as template primer. Anal Biochem 180:22-229, 1989
26. Rodriguez CO Jr, Legha JK, Estey E: Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res 3:2107-2113, 1997
27. Gandhi V, Plunkett W: Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharm 38:3551-3558, 1989
28. Kufe DW, Major PP, Egan EM, et al: Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255:8997-9000, 1980
29. Kufe D, Spriggs D, Egan EM, et al: Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64:54-58, 1984
30. Spriggs D, Robbins G, Mitchell T, et al: Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular DNA and RNA. Biochem Pharm 35:247-252, 1986
31. Huang P, Chubb S, Plunkett W: Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate. A mechanism of toxicity. J Biol Chem 265:16617-16625, 1990
32. Huang P, Chubb S, Hertel LW, et al: Actions of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
33. Rodriguez CO, Gandhi V: Incorporation of arabinosylguanine into DNA is necessary for cell death (apoptosis). Proc Am Assoc Cancer Res 39:470, 1998 (abstr)
34. Huang P, Robertson LE, Wright S, et al: High molecular weight DNA fragmentation: A critical event in nucleoside analog-induced apoptosis in leukemia cells. Clin Cancer Res 1:1005-1013, 1995
35. Ono K, Ohashi A, Yamamoto A, et al: Inhibitory effects of 9-β-D-arabinofuranosylguanine 5′-triphosphate and 9-β-D-arabinofuranosyladenine 5′-triphosphate on DNA polymerases from murine cells and oncornavirus. Cancer Res 39:4673-4680, 1979
36. Gandhi V, Mineishi S, Huang P, et al: Cytotoxicity, metabolism, and mechanisms of action of 2′,2′-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res 55:1517-1524, 1995
37. Gandhi V, Mineishi S, Huang P, et al: Difluorodeoxyguanosine: Cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol 22:61-67, 1995
38. Gandhi V, Rodriguez CO, Kisor DF, et al: Rationale and design of pharmacologically directed clinical trials of GW506U in refractory hematologic malignancies. Blood 90:3824, 1997 (suppl 1, abstr)